Michael Thomas Henderson insider trades: Apogee Therapeutics (APGE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
Open-market buys and sales
39 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | APGE | ↓ Sell | 20,000 | $133.63 | $2.7M | Direct | Jul 10, 2026 (2d) |
| Jun 22, 2026 | APGE | ↓ Sell | 80,000 | $132.54 | $10.6M | Direct | Jun 24, 2026 (2d) |
| Jun 22, 2026 | SYRE | ↓ Sell | 20,000 | $100.00 | $2.0M | Direct | Jun 23, 2026 (1d) |
| Jun 10, 2026 | APGE | ↓ Sell | 20,000 | $83.38 | $1.7M | Direct | Jun 12, 2026 (2d) |
| May 13, 2026 | APGE | ↓ Sell | 20,000 | $82.09 | $1.6M | Direct | May 15, 2026 (2d) |
| May 8, 2026 | SYRE | ↓ Sell | 80,000 | $74.40 | $6.0M | Direct | May 8, 2026 (0d) |
| Apr 8, 2026 | APGE | ↓ Sell | 20,000 | $82.58 | $1.7M | Direct | Apr 10, 2026 (2d) |
| Feb 11, 2026 | APGE | ↓ Sell | 20,000 | $63.35 | $1.3M | Direct | Feb 13, 2026 (2d) |
| Jan 14, 2026 | APGE | ↓ Sell | 20,000 | $81.11 | $1.6M | Direct | Jan 16, 2026 (2d) |
| Dec 10, 2025 | APGE | ↓ Sell | 20,000 | $75.38 | $1.5M | Direct | Dec 12, 2025 (2d) |
| Dec 4, 2025 | APGE | ↓ Sell | 40,000 | $75.01 | $3.0M | Direct | Dec 5, 2025 (1d) |
| Nov 13, 2025 | APGE | ↓ Sell | 20,000 | $63.01 | $1.3M | Direct | Nov 13, 2025 (0d) |
| Mar 5, 2025 | APGE | ↓ Sell | 10,000 | $30.15 | $302K | Direct | Mar 7, 2025 (2d) |
| Feb 5, 2025 | APGE | ↓ Sell | 15,000 | $40.58 | $609K | Direct | Feb 7, 2025 (2d) |
| Jan 8, 2025 | APGE | ↓ Sell | 15,000 | $48.85 | $733K | Direct | Jan 10, 2025 (2d) |
| Dec 4, 2024 | APGE | ↓ Sell | 15,000 | $46.58 | $699K | Direct | Dec 6, 2024 (2d) |
| Nov 6, 2024 | APGE | ↓ Sell | 15,000 | $59.22 | $888K | Direct | Nov 8, 2024 (2d) |
| Oct 2, 2024 | APGE | ↓ Sell | 40,000 | $56.23 | $2.2M | Direct | Oct 4, 2024 (2d) |
| Sep 4, 2024 | APGE | ↓ Sell | 40,000 | $47.62 | $1.9M | Direct | Sep 6, 2024 (2d) |
| Aug 7, 2024 | APGE | ↓ Sell | 40,000 | $40.62 | $1.6M | Direct | Aug 9, 2024 (2d) |
| Jul 5, 2024 | APGE | ↓ Sell | 15,000 | $37.26 | $559K | Direct | Jul 5, 2024 (0d) |
| Dec 1, 2020 | BBIO | ↓ Sell | 10,000 | $51.52 | $515K | Direct | Dec 2, 2020 (1d) |
| Nov 16, 2020 | BBIO | ↓ Sell | 10,000 | $45.00 | $450K | Direct | Nov 18, 2020 (2d) |
| Nov 2, 2020 | BBIO | ↓ Sell | 10,000 | $38.36 | $384K | Direct | Nov 3, 2020 (1d) |
| Oct 1, 2020 | BBIO | ↓ Sell | 10,000 | $38.83 | $388K | Direct | Oct 5, 2020 (4d) |
| Sep 18, 2020 | BBIO | ↓ Sell | 10,000 | $40.00 | $400K | Direct | Sep 22, 2020 (4d) |
| Sep 1, 2020 | BBIO | ↓ Sell | 10,000 | $28.73 | $287K | Direct | Sep 3, 2020 (2d) |
| Aug 3, 2020 | BBIO | ↓ Sell | 10,000 | $27.37 | $274K | Direct | Aug 5, 2020 (2d) |
| Jul 1, 2020 | BBIO | ↓ Sell | 10,000 | $30.97 | $310K | Direct | Jul 6, 2020 (5d) |
| Jun 8, 2020 | BBIO | ↓ Sell | 606 | $30.01 | $18K | Direct | Jun 10, 2020 (2d) |
| Jun 3, 2020 | BBIO | ↓ Sell | 784 | $30.04 | $24K | Direct | Dec 2, 2020 (182d) |
| Jun 1, 2020 | BBIO | ↓ Sell | 2,585 | $29.37 | $76K | Direct | Jun 3, 2020 (2d) |
| May 5, 2020 | BBIO | ↓ Sell | 1,460 | $30.47 | $44K | Direct | May 6, 2020 (1d) |
| May 4, 2020 | BBIO | ↓ Sell | 3,905 | $29.52 | $115K | Direct | May 5, 2020 (1d) |
| Apr 1, 2020 | BBIO | ↓ Sell | 2,585 | $26.94 | $70K | Direct | Apr 3, 2020 (2d) |
| Mar 2, 2020 | BBIO | ↓ Sell | 3,975 | $32.44 | $129K | Direct | Mar 4, 2020 (2d) |
| Feb 3, 2020 | BBIO | ↓ Sell | 3,975 | $34.90 | $139K | Direct | Feb 5, 2020 (2d) |
| Jan 3, 2020 | BBIO | ↓ Sell | 3,975 | $33.17 | $132K | Direct | Jan 6, 2020 (3d) |
| Jul 1, 2019 | BBIO | ↑ Buy | 7,000 | $17.00 | $119K | Direct | Jul 3, 2019 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other APGE insiders
Open-market trades in the last 12 months
About Michael Thomas Henderson's insider trades
Michael Thomas Henderson is Chief Executive Officer at Apogee Therapeutics (APGE). Since Jul 1, 2019, Michael has reported 1 open-market purchase worth $119K and 38 sales worth $48.2M on SEC Form 4. In the last 12 months: 12 sales ($34.8M).
Their filings also include option exercises (12 filings), grants and awards (8 filings), shares returned to the company (2 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every APGE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.